William D Tap

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma
    William D Tap
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
    Neoplasia 12:637-49. 2010
  2. doi Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization
    William D Tap
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
    Genes Chromosomes Cancer 50:95-112. 2011
  3. ncbi Targeted therapies for soft-tissue sarcomas
    William D Tap
    UCLA Sarcoma Program, Division of Hematology Oncology, Los Angeles, CA 90095 7059, USA
    Expert Rev Anticancer Ther 7:725-33. 2007
  4. pmc 18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy
    Ken Herrmann
    Division of Surgical Oncology, University of California at Los Angeles, 10833 Le Conte Avenue, Rm 54 140 CHS, Los Angeles, CA 90095, USA
    Clin Cancer Res 18:2024-31. 2012
  5. pmc 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response
    Matthias R Benz
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095 1782, USA
    Cancer 118:3135-44. 2012
  6. pmc Novel dedifferentiated liposarcoma xenograft models reveal PTEN down-regulation as a malignant signature and response to PI3K pathway inhibition
    Kathleen B Smith
    Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California 90095, USA
    Am J Pathol 182:1400-11. 2013
  7. pmc Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign
    Matthias R Benz
    Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California 90095 1782, USA
    Cancer 116:451-8. 2010
  8. doi FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas
    Matthias R Benz
    Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095 1782, USA
    Clin Cancer Res 15:2856-63. 2009
  9. doi Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma
    Nicholas M Bernthal
    Department of Orthopedics, UCLA Orthopedic Hospital, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California 90095 1782, USA
    Cancer 118:5888-93. 2012
  10. pmc FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas
    Matthias R Benz
    Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095 1782, USA
    Sarcoma 2010:143540. 2010

Collaborators

Detail Information

Publications20

  1. pmc Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma
    William D Tap
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
    Neoplasia 12:637-49. 2010
    ..We sought to investigate the efficacy of PLX4032 (BRAF inhibitor) to identify patterns/predictors of response/resistance and to study the effects of BRAF in melanoma...
  2. doi Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization
    William D Tap
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
    Genes Chromosomes Cancer 50:95-112. 2011
    ..This detailed genetic mapping provides insight into the heterogeneity of WD and DDLS and the chromosomal and genetic abnormalities that are present in and distinguish these mesenchymal malignancies...
  3. ncbi Targeted therapies for soft-tissue sarcomas
    William D Tap
    UCLA Sarcoma Program, Division of Hematology Oncology, Los Angeles, CA 90095 7059, USA
    Expert Rev Anticancer Ther 7:725-33. 2007
    ..This review will outline current areas of therapeutic interest in soft-tissue sarcomas with regard to agents that have reached clinical testing...
  4. pmc 18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy
    Ken Herrmann
    Division of Surgical Oncology, University of California at Los Angeles, 10833 Le Conte Avenue, Rm 54 140 CHS, Los Angeles, CA 90095, USA
    Clin Cancer Res 18:2024-31. 2012
    ..We prospectively evaluated whether 2[18F]fluoro-2-deoxy-d-glucose ((18)F-FDG)-PET/computed tomographic (CT) imaging after the initial cycle of neoadjuvant therapy could predict overall survival in these patients...
  5. pmc 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response
    Matthias R Benz
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095 1782, USA
    Cancer 118:3135-44. 2012
    ....
  6. pmc Novel dedifferentiated liposarcoma xenograft models reveal PTEN down-regulation as a malignant signature and response to PI3K pathway inhibition
    Kathleen B Smith
    Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California 90095, USA
    Am J Pathol 182:1400-11. 2013
    ..These human xenograft models may facilitate liposarcoma research and accelerate the generation of readily translatable preclinical data that could ultimately influence patient care...
  7. pmc Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign
    Matthias R Benz
    Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California 90095 1782, USA
    Cancer 116:451-8. 2010
    ..The aim of this study was to evaluate whether F18-fluorodeoxyglucose positron emission tomography (FDG PET) can differentiate malignant (MPNST) from benign PNSTs...
  8. doi FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas
    Matthias R Benz
    Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095 1782, USA
    Clin Cancer Res 15:2856-63. 2009
    ....
  9. doi Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma
    Nicholas M Bernthal
    Department of Orthopedics, UCLA Orthopedic Hospital, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California 90095 1782, USA
    Cancer 118:5888-93. 2012
    ..In addition, the value of pathologic necrosis induced by a single cycle of neoadjuvant chemotherapy was analyzed as a predictive marker of disease-free and overall survival...
  10. pmc FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas
    Matthias R Benz
    Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095 1782, USA
    Sarcoma 2010:143540. 2010
    ..Conclusion. These results suggest that changes in FDG-SUVmax at the end of neoadjuvant treatment can identify histopathologic responders and non-responders in adult primary bone sarcoma patients...
  11. pmc Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
    Gary K Schwartz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet Oncol 14:371-82. 2013
    ....
  12. doi Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas
    Bartosz Chmielowski
    Department of Medicine, Division of Hematology Oncology, David Geffen School of Medicine, University of California Los Angeles, Santa Monica, CA 90404, USA
    Expert Rev Anticancer Ther 12:1217-28. 2012
    ....
  13. doi Evaluation of neoadjuvant therapy and histopathologic response in primary, high-grade retroperitoneal sarcomas using the sarcoma nomogram
    Timothy R Donahue
    Department of Surgery, Division of Surgical Oncology, University of California at Los Angeles, Los Angeles, California 90095 1782, USA
    Cancer 116:3883-91. 2010
    ..Patients with primary high-grade retroperitoneal soft tissue sarcomas have a 5-year disease-specific survival (DSS) of <40%. The impact of neoadjuvant therapy on histopathologic response and DSS are unknown...
  14. doi Utilization of positron emission tomography in the management of patients with sarcoma
    Matthias R Benz
    Departments of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California 90095, USA
    Curr Opin Oncol 21:345-51. 2009
    ..In this review, the recent literature covering all aspects of PET imaging in the management of patients with soft tissue and bone sarcomas will be discussed...
  15. pmc Metabolomics strategy reveals subpopulation of liposarcomas sensitive to gemcitabine treatment
    Daniel Braas
    Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California 90095, USA
    Cancer Discov 2:1109-17. 2012
    ..These data suggest that a subpopulation of liposarcoma patients have tumors with nucleoside salvage pathway activity that can be identified noninvasively using [18F]-FAC-PET and targeted using gemcitabine...
  16. doi The multidisciplinary management of osteosarcoma
    Noah Federman
    Division of Pediatric Hematology Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Curr Treat Options Oncol 10:82-93. 2009
    ..The treatment of metastatic, recurrent and/or refractory disease is more controversial. Despite advances in systemic treatment, surgical technique, and supportive care, the overall outcome is still poor...
  17. ncbi Pediatric sarcomas: translating molecular pathogenesis of disease to novel therapeutic possibilities
    Jennifer L Anderson
    Molecular Biology Interdepartmental PhD Program, University of California, Los Angeles, USA
    Pediatr Res 72:112-21. 2012
    ..This review summarizes the molecular pathology of a subset of pediatric sarcomas with tumor-associated translocations and how increased understanding at the molecular level is being translated to novel therapeutic advances...
  18. ncbi Advances in chemotherapy for patients with extremity soft tissue sarcoma
    Fritz C Eilber
    University of California, Los Angeles, UCLA Medical Center, 90095 1782, USA
    Orthop Clin North Am 37:15-22. 2006
    ..Until a less toxic targeted systemic therapy is developed, treatment with ifosfamide should be strongly considered in patients who have high-risk primary extremity soft tissue sarcomas...
  19. doi Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors
    William D Tap
    University of California, Los Angeles Medical Center, Los Angeles, CA, USA
    J Clin Oncol 30:1849-56. 2012
    ..An open-label phase II study was conducted to evaluate the efficacy and safety of ganitumab monotherapy in patients with metastatic Ewing family tumors (EFT) or desmoplastic small round cell tumors (DSRCT)...
  20. doi Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas
    Vladimir Evilevitch
    Abteilung Nuklearmedizin University of Freiburg, Freiburg, Germany
    Clin Cancer Res 14:715-20. 2008
    ..The aim of this study was to prospectively evaluate whether positron emission tomography with (18)F-fluorodeoxyglucose (FDG-PET) allows for a more accurate evaluation of histopathologic response...